Do you want to read an article? Please log in or register.
Atezolizumab for First-Line Treatment of PD-L1-Selected Patients with NSCLC
Lung, Respiratory and Thoracic Cancer
Related content
Central Nervous System TumorsLung, Respiratory and Thoracic Cancer
Significant Survival Benefit of Atezolizumab in Second-Line NSCLC Regardless of PD-L1 Status (The OAK Study)
RECOMMENDED
Lung, Respiratory and Thoracic Cancer
Post-progression outcomes of NSCLC patients with PD-L1 expression ≥ 50% receiving first-line single-agent pembrolizumab in a large multicentre real-world study
★ 1
Recommended by
Dr Wolf-Dieter Janthur, Faculty Member
Eur J Cancer
Cortellini A, Cannita K, Tiseo M, Cortinovis DL, Aerts JGJV, Baldessari C, Giusti R, Ferrara MG, D'Argento E, Grossi F, Guida A, Berardi R, Morabito A, Genova C, Antonuzzo L, Mazzoni F, De Toma A, Signorelli D, Gelibter A, Targato G, Rastelli F, Chiari R, Rocco D, Gori S, De Tursi M, Mansueto G, Zoratto F, Filetti M, Bracarda S, Citarella F, Marco R, Cantini L, Nigro O, Buti S, Minuti G, Landi L, Ricciardi S, Migliorino MR, Natalizio S, Simona C, De Filippis M, Metro G, Adamo V, Russo A, Spinelli GP, Di Maio M, Banna GL, Friedlaender A, Addeo A, Pinato DJ, Ficorella C, Porzio G
doi: 10.1016/j.ejca.2021.02.005
Gastrointestinal CancerLung, Respiratory and Thoracic Cancer
Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC
N Engl J Med.
Socinski MA, Jotte RM, Cappuzzo F, Orlandi F, Stroyakovskiy D, Nogami N, Rodríguez-Abreu D, Moro-Sibilot D, Thomas CA, Barlesi F, Finley G, Kelsch C, Lee A, Coleman S, Deng Y, Shen Y, Kowanetz M, Lopez-Chavez A, Sandler A, Reck M; IMpower150 Study Group
doi: 10.1056/NEJMoa1716948.
Breast Cancer
Recent Developments in Metastatic Breast Cancer
healthbook TIMES Oncology Hematology
Lung, Respiratory and Thoracic Cancer
Outcomes to first-line pembrolizumab in patients with non-small cell lung cancer and very high PD-L1 expression
Ann Oncol.
Aguilar EJ, Ricciuti B, Gainor JF, Kehl KL, Kravets S, Dahlberg S, Nishino M, Sholl LM, Adeni A, Subegdjo S, Khosrowjerdi S, Peterson RI, Digumarthy S, Liu C, Sauter J, Rizvi H, Arbour KC, Carter BW, Heymach JV, Altan M, Hellmann MD, Awad MM
doi: 10.1093/annonc/mdz288.
Lung, Respiratory and Thoracic Cancer
Outcomes to first-line pembrolizumab in patients with non-small-cell lung cancer and very high PD-L1 expression
Ann Oncol.
Aguilar EJ, Ricciuti B, Gainor JF, Kehl KL, Kravets S, Dahlberg S, Nishino M, Sholl LM, Adeni A, Subegdjo S, Khosrowjerdi S, Peterson RM, Digumarthy S, Liu C, Sauter J, Rizvi H, Arbour KC, Carter BW, Heymach JV, Altan M, Hellmann MD, Awad MM
doi: 10.1093/annonc/mdz288.
Lung, Respiratory and Thoracic Cancer
Cost effectiveness of pembrolizumab vs chemotherapy as first-line treatment for metastatic NSCLC that expresses high levels of PD-L1 in Switzerland
Swiss Med Wkly.
Bhadhuri A, Insinga R, Guggisberg P, Panje C, Schwenkglenks M
doi: 10.4414/smw.2019.20170.
Gastrointestinal CancerLung, Respiratory and Thoracic Cancer
Mini Review: Erlotinib as first-line treatment for NSCLC – an overview of the data currently available
Wolf-Dieter Janthur
FMH specialist in oncology
Senior physician,
Aarau Canton Hospital
Consultant doctor to Muri Hospital
Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial
Lancet.
Balar AV, Galsky MD, Rosenberg JE, Powles T, Petrylak DP, Bellmunt J, Loriot Y, Necchi A, Hoffman-Censits J, Perez-Gracia JL, Dawson NA, van der Heijden MS, Dreicer R, Srinivas S, Retz MM, Joseph RW, Drakaki A, Vaishampayan UN, Sridhar SS, Quinn DI, Durán I, Shaffer DR, Eigl BJ, Grivas PD, Yu EY, Li S, Kadel EE 3rd, Boyd Z, Bourgon R, Hegde PS, Mariathasan S, Thåström A, Abidoye OO, Fine GD, Bajorin DF; IMvigor210 Study Group
doi: 10.1016/